Connect your AI

Anika Therapeutics ANIK Earnings yield

Earnings yield at other companies

StrykerSYK

2.7%+0.6pp

VericelVCEL

1.3%+1.2pp

Zimmer Biomet HoldingsZBH

4.3%+0.2pp

Pacira BioSciences, Inc.PCRX

0.6%—

BioventusBVS

4.6%+3.0pp

Xtant Medical HoldingsXTNT

2.3%+1.2pp

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

net income/market cap=-5.8%

Based on trailing twelve months.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's earnings yield?: Anika Therapeutics (ANIK) reported earnings yield of -5.8% in Q1 2026.
How has Anika Therapeutics's earnings yield changed year-over-year?: Anika Therapeutics's earnings yield increased by 78.1% year-over-year, from -26.6% to -5.8%.
What is the long-term trend for Anika Therapeutics's earnings yield?: Over 4 years (2020 to 2025), Anika Therapeutics's earnings yield has grown at a 21.7% compound annual growth rate (CAGR), from -3.7% to -8.1%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.